The agency said the $7.1 billion acquisition "would stifle competition and innovation in the U.S. market for life-saving cancer tests."April 4, 2023Check out STAT+Sponsored By Adobe STAT+ | FTC tells Illumina to divest Grail, boosting Icahn's case The agency said the $7.1 billion acquisition "would stifle competition and innovation in the U.S. market for life-saving cancer tests." By Matthew Herper STAT+ | The biotech scorecard for the second quarter: 24 stock-moving events to watch What to watch in Q2, including an advisory committee for Sarepta Therapeutics, results from Immunogen, and readouts from Fibrogen. By Adam Feuerstein Why the early tests of ChatGPT in medicine miss the mark The early tests of GPT in health care have only examined its textbook knowledge — not its ability to help doctors make decisions. By Casey Ross More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments